{"id":"NCT00004563","sponsor":"The University of Texas Health Science Center, Houston","briefTitle":"Scleroderma Lung Disease","officialTitle":"Cyclophosphamide Versus Placebo in Scleroderma Lung Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1999-08","primaryCompletion":"2013-05","completion":"2013-05","firstPosted":"2000-02-10","resultsPosted":"2015-03-06","lastUpdate":"2015-03-27"},"enrollment":158,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Lung Diseases","Pulmonary Fibrosis","Systemic Scleroderma","Scleroderma, Systemic"],"interventions":[{"type":"DRUG","name":"Cyclophosphamide","otherNames":["Cytoxan (Bristol Myers Squibb)"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cylophosphamide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of cyclophosphamide versus placebo for the prevention and progression of symptomatic pulmonary disease in patients with systemic sclerosis.","primaryOutcome":{"measure":"Forced Vital Capacity","timeFrame":"12 months","effectByArm":[{"arm":"Cylophosphamide","deltaMin":66.6,"sd":1.7},{"arm":"Placebo","deltaMin":65.6,"sd":1.6}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["16790698","30651141","29099620","28544580","26757749","26704522","25452309","22156609","21547897","19892673","18641099","17901414","17717203"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":79},"commonTop":["Leukopenia","Hematuria","Neutropenia","Pneumonia"]}}